retigabine/ezogabine
PreclinicalSmall molecule
GSKretigabine/ezogabine is one of 24 small molecule programs targeting Partial Epilepsy. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Partial Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Vimpat
UCBApproved
Trileptal
NovartisApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Depakote
AbbVieApproved
Zonegran
AAzurity Pharmaceuticals
Approved
Topamax
WWim Janssens
Approved
Valium
Akero TherapeuticsApproved
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pediatric1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for retigabine/ezogabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]